Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or major omissions.
300630SZSE
Announcement on the Conversion of Convertible Bonds in Q1 2025 and Related Risk Warnings for Stock and Convertible Bond Trading
✨ AI Summary
This announcement details the conversion of 3,288,594 convertible bonds into 109,533,626 shares of Hainan Puli Pharmaceutical Co., Ltd. in Q1 2025. As of March 31, 2025, there are 2,022,669 convertible bonds remaining. The company faces potential delisting due to false disclosures in its 2021 and 2022 annual reports, leading to a trading suspension from March 24, 2025.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.